The UK Kidney Association has released its Clinical Practice Guideline on sodium–glucose cotransporter 2 (SGLT2) inhibitor use in adults with kidney disease. Studies have demonstrated that these agents have particular efficacy at reducing risk of kidney disease progression in people with type 2 diabetes and albuminuric diabetic kidney disease, and that these benefits may extend to certain types of albuminuric renal disease irrespective of the presence of diabetes.
Therefore, the aim of the guidelines is to facilitate rapid and safe use of SGLT2 inhibitors in the context of chronic kidney disease, focusing on the potential to modify risk of kidney disease progression, and to support the safe implementation of SGLT2 inhibitors in clinical practice.
Click here to read the guideline.
